MedTrace Logo

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

NCT02396433 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2015-08-25

No results posted yet for this study

Summary

Non-randomized, open-label, multi-center, phase I/II, dose-escalation study of the combination of carboplatin, eribulin, and E7449.

Conditions

  • Cancer of the Breast

Interventions

DRUG

Carboplatin

Carboplatin will be given on day 1 of each cycle.

DRUG

Eribulin

Eribulin will be given on days 1 and 8 of each cycle.

DRUG

E7449

E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Virginia Kaklamani · UTHSCSA@CTRC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-04-30
Completion
2015-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02396433 on ClinicalTrials.gov